


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SINO BIOPHARMACEUTICAL LIMITED**  
**中國生物製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

*Website: [www.sinobiopharm.com](http://www.sinobiopharm.com)*

**(Stock code: 1177)**

**VOLUNTARY ANNOUNCEMENT**  
**ACQUISITION OF SOFTHALE**

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that on 22 March 2021, C-Lab International Limited, a wholly-owned subsidiary of the Company, entered into an agreement in relation to a 100% acquisition (the “**Acquisition**”) of SOFTHALE NV (“**Softhale**”) for US\$110 million and additional payments related to regulatory and commercial milestones. Softhale is a privately owned Belgian company focused on the development of products for the treatment of respiratory diseases. Its next generation Soft Mist Inhalation (“**SMI**”) device is based upon differentiated technology and allows for more efficient drug deposition into the lungs. The Acquisition will be funded by internal resources of the Group.

The Board considers that the Acquisition is in the interests of the Company and its shareholders for the following strategic significance:

1. Solidifies the Group’s leading position in the respiratory therapeutic area by offering next generation inhaler technology that provides chronic obstructive pulmonary diseases (“**COPD**”) and asthma patients with a more effective product which is complementary to the Group’s existing inhaler product portfolio by covering different COPD patient groups.
2. Enhances the Group’s transformation from generics to innovation player by acquiring and fully controlling its own respiratory research and development capability. Softhale has its own intellectual property and patents to support the development of SMI technology with the potential to enable new compounds/drugs and expand into other non-respiratory therapeutic areas.
3. Accelerates the Group’s internationalization strategy by establishing a local hub in Europe as well as developing products with significant global market potential.

The Group was advised by Results Healthcare (Merger and Acquisition), Bakers McKenzie (Legal), Ernst & Young (Financial and Tax), Theraproval (Regulatory) and Carpmaels & Ransford (Intellectual Property) on the Acquisition.

The Board believes that Softhale will provide a key strategic hub in Europe to the Group and expects that the company will become an important developer of innovative respiratory products for China and the global market.

By order of the Board  
**Sino Biopharmaceutical Limited**  
**Tse, Theresa Y Y**  
*Chairwoman*

Hong Kong, 23 March 2021

*As at the date of this announcement, the Board of the Company comprises nine Executive Directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Li Yi, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and five Independent Non-Executive Directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Mr. Li Kwok Tung Donald.*